The Use of PDX1 DNA Methylation to Distinguish Two Subtypes of Pancreatic Neuroendocrine Neoplasms with Different Prognoses

Hendrik Ungefroren; Björn Konukiewitz; Ulrich F Wellner; Jörg Schrader; Tobias Keck

doi:10.3390/cancers15010160

The Use of PDX1 DNA Methylation to Distinguish Two Subtypes of Pancreatic Neuroendocrine Neoplasms with Different Prognoses

Cancers (Basel). 2022 Dec 27;15(1):160. doi: 10.3390/cancers15010160.

Authors

Hendrik Ungefroren^{1

2}, Björn Konukiewitz², Ulrich F Wellner³, Jörg Schrader⁴, Tobias Keck³

Affiliations

¹ First Department of Medicine, University Hospital Schleswig-Holstein (UKSH), Campus Lübeck, 23538 Lübeck, Germany.
² Institute of Pathology, University Hospital Schleswig-Holstein (UKSH), Campus Kiel, 23538 Lübeck, Germany.
³ Department of Surgery, University Hospital Schleswig-Holstein (UKSH), Campus Lübeck, 23538 Lübeck, Germany.
⁴ First Department of Medicine, University Hospital Hamburg-Eppendorf, 20251 Hamburg, Germany.

Abstract

Pancreatic neuroendocrine neoplasms (pNENs) account for approximately 5% of all pancreatic tumors; thus, they constitute the second most common tumor type in the pancreas [...].

Publication types

Editorial